Trial Simulation, Drug Selection To Be Focus Of US FDA's Drug Development Modeling Pilot

The US FDA is set to begin accepting requests to participate in its model-informed drug development (MIDD) pilot program, but the agency will "initially prioritize" meeting requests from sponsors that focus on dose selection, clinical trial simulation and predictive or mechanistic safety evaluation.